RxDoctor Payments Data

Sarah Jancek, DO

Internal Medicine · Dartmouth, MANPI 1689815102

Payments from drug & device makers

$923in general payments, 2019–2025

Across 56 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147
  • Novartis$137
  • Johnson & Johnson$113
  • AstraZeneca$77
  • Lilly USA, LLC$70
  • Pfizer$69
  • plus $310 from 12 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$376,400
Medicare patients
840
Services billed
3,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$84,319
TrulicityDulaglutide86$65,389
BiktarvyBictegrav/Emtricit/Tenofov Ala37$38,646
XifaxanRifaximin29$25,460
JardianceEmpagliflozin92$19,374
MyrbetriqMirabegron112$17,505
JanuviaSitagliptin Phosphate71$15,079
XareltoRivaroxaban60$12,972
RybelsusSemaglutide12$11,771
CreonLipase/Protease/Amylase14$11,010
TradjentaLinagliptin55$10,440
LinzessLinaclotide44$9,384
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$8,694
BelsomraSuvorexant22$8,156
RexultiBrexpiprazole17$7,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$84,319410 claims
Lilly USA, LLCTrulicity, Humalog$70$67,215110 claims
Boehringer IngelheimJardiance, Tradjenta$16$29,814147 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$26$25,46029 claims
MerckJanuvia, Belsomra$25$23,23593 claims
AbbVieCreon, Linzess$16$20,39458 claims
Novo NordiskRybelsus, Levemir, Novolog$147$15,38749 claims
Johnson & JohnsonXarelto$113$12,97260 claims
GSKTrelegy Ellipta$25$8,69417 claims
AstraZenecaFarxiga$77$5,98426 claims
Sanofi-aventis U.S. LLCLantus$13$3,49846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →